In vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir

Remdesivir (RDV, Veklury®) is an FDA-approved prodrug for the treatment of hospitalized patients with COVID-19. Recent in vitro studies have indicated that human carboxylesterase 1 (CES1) is the major metabolic enzyme catalyzing RDV activation. COVID-19 treatment for hospitalized patients typically...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qingchen, Melchert, Philip W., Markowitz, John S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367181/
https://www.ncbi.nlm.nih.gov/pubmed/35964681
http://dx.doi.org/10.1016/j.cbi.2022.110097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367181/
https://www.ncbi.nlm.nih.gov/pubmed/35964681
http://dx.doi.org/10.1016/j.cbi.2022.110097

Ejemplares similares